134062-32-1

Upstream product

• 79-24-3 Nitroethane 
• 591-31-1 3-methoxy-benzaldehyde 

Downstream Products

• 112649-81-7 N-<α-Methyl-β-(3-methoxyphenyl)ethyl>propanamide 
• 112649-86-2 (Z)-1-Ethylidene-1,2,3,4-tetrahydro-6-methoxy-2-(3-methoxybenzoyl)-3-methylisoquinoline 
• 1453201-20-1 (R)-1-methoxy-3-(2-nitropropyl)benzene 
• 1618668-92-0 (S)-1-methoxy-3-(2-nitropropyl)benzene 
• 69390-44-9 (E)-N-(1-(3-methoxyphenyl)prop-1-en-2-yl)acetamide 
• 17862-85-0 3-methoxyamphetamine 
• 29865-53-0 1-(3'-methoxyphenyl)-2-nitropropane 

Relevant academic research and scientific papers

Enantioselective hydrogenation of α,β-disubstituted nitroalkenes

The first highly chemo- and enantioselective hydrogenation of α,β-disubstituted nitroalkenes was accomplished with rhodium/JosiPhos-J2 as a catalyst, with the yield and enantioselectivity of up to 95% and 94%, respectively. The α-chiral nitroalkanes will provide an entry to valuable chiral amphetamines which are otherwise not so easily accessed. This journal is the Partner Organisations 2014.

Design of phosphorus ligands with deep chiral pockets: Practical Synthesis of chiral β-arylamines by asymmetric hydrogenation

WingPhos, a C2-symmetric bisphosphorus ligand with a deep and well-defined chiral pocket was developed. It has shown high efficiency in the rhodium-catalyzed asymmetric hydrogenation of (E)-β-aryl-N-acetyl enamides, cyclic β-aryl enamides, and heterocyclic β-aryl enamides. A series of chiral β-arylisopropylamines, 2-aminotetralines, and 3-aminochromans can be synthesized with excellent ee values (nbd=3,5-norbornadiene; TON=turnover number). Copyright

An efficient synthesis of (E)-nitroalkenes catalyzed by recoverable diamino-functionalized mesostructured polymers

A clean, efficient, and simple method has been developed for synthesis of (E)-nitroalkenes using FDU-ED as an efficient catalyst. The reactions proceeded with moderate to high yields (60-96%) under mild conditions. The catalyst FDU-ED is recyclable and can be reused more than seven times without significant loss of activity and selectivity.

Asymmetric reduction of nitroalkenes with baker's yeast

Various α,β-disubstituted and trisubstituted nitroalkenes were chemoselectively reduced with baker's yeast to the corresponding nitroalkanes. Stereoselectivities of the reduction of α,β-disubstituted nitroalkenes were modest to low, and e.e.s up to 52% were obtained. Trisubstituted nitroalkenes could be reduced to the corresponding nitroalkanes with excellent enantioselectivities, moderate diastereoselectivities and in good yield.

HENRY CONDENSATION UNDER HIGH PRESSURE. 2. EFFECT OF AROMATIC ALDEHYDE TYPE AND PRESSURE ON THE YIELD OF ω-NITROSTYRENES AND SECONDARY PROCESSES

Condensation of aromatic aldehydes (I)-(XX) with EtNO2 and n-PrNO2 in AcOH in the presence of AcONH4 or i-BuNH2 gives primarily ω-nitrostyrenes (Ia, b) - (XXa, b) and small quantities of nitriles (Ic) - (XXc), oximes (Id) - (XXd), and ketones (Ie, f) - (XXe, f).The yields of (Ia, b) - (XXa, b) at P = 1 atm are higher for acceptor substitutents on the aromatic ring whereas at P = 10 kbar, they are higher for donor substituents.High pressures suppress the formation of (Ic-f) - (XXc-f) and the Z-isomers of (Ia, b) - (XXa, b).The high pressure technique is especially useful in the preparation of donor-substituted (Ia, b) - (XXa, b) which are intermediates in the synthesis of the psychotropic β-phenylethylamines.

Methods for the treatment of hypertension

Acetylene compounds of the formula (I): STR1 wherein Y, R1, R2, R3, and R4 are as described herein, m is 0-3, n is 0-2 and Ar is phenyl or an aromatic heterocycle are disclosed. The compounds possess antihyperte

3,10-Dimethoxyprotoberberines

Protoberberines with the unusual 3,10-dimethoxy substitution are synthesized by photocyclization of E- and Z-1-ethylidene-1,2,3,4-tetrahydro-6-methoxy-2-(3-methoxybenzoyl)isoquinolines.

Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives

Acetylenes of the formula (I): STR1 wherein Y, m, R1, R2 q, Alk, R3, n and R4 are as defined herein and Ar1 and Ar2 are aromatic, including the salts and ammonium derivatives of formula (I), in treating angina, hypertension and cardiac arrhythmias. Pharmaceutical compositions, methods of use and synthesis and novel intermediates are also part of the invention.